FDA Clears iRhythm’s Afib-Detecting Wearable Running Software Co-Developed By Verily
The ZEUS (Zio ECG Utilization Software) system for iRhythm’s Zio Watch detects and characterizes atrial fibrillation over time to aid doctors in diagnosing the condition. The company expects to begin commercializing it next year.
You may also be interested in...
In this month’s Digital Health roundup, Medtech Insight’s Reed Miller talks about iRhythm and Withings’ smartwatches business, Barnaby Pickering reviews digital therapeutics Pear Therapeutics’ restructuring, and Marion Webb presents highlights from her new series on Agetech.
Quentin Blackford, who recently became iRhythm’s CEO after serving as Dexcom’s chief operating officer, talked to Medtech Insight about the challenges and opportunities in the emerging remote cardiac monitoring market.
Despite intense lobbying from industry and physician groups, CMS chose not to install national pricing for long-term remote cardiac monitoring in its final 2022 Medicare Physician Fee Schedule Final Rule.